Carcinoid
14
4
5
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
7.1%
1 terminated out of 14 trials
80.0%
-6.5% vs benchmark
14%
2 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Natural History of Familial Carcinoid Tumor
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
DOTATOC PET/CT for Imaging NET Patients
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
EPO906 in Carcinoid and Other Neuroendocrine Tumors
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features